C.J., et al., An aggrecan-degrading
activity associated with chondrocyte membranes.
Biochem. J., 336, 207-12 (1998).
7. Ishiguro, N., et al., Relationship of matrix
metalloproteinases and their inhibitors
in liposome
preparations. Biochim. Biophys. Acta., 210(3),
486-489 (1970).
8. Ackerman, C. J., and Salmon, W. D., Anal.
Biochem., 1, 327-336 (1960).
9. Singleton, W. S., et al., J. Am. Oil Chem
in liposome
preparations. Biochim. Biophys. Acta., 210(3),
486-489 (1970).
8. Ackerman, C. J., and Salmon, W. D., Anal.
Biochem., 1, 327-336 (1960).
9. Singleton, W. S., et al., J. Am. Oil Chem
in liposome
preparations. Biochim. Biophys. Acta., 210(3),
486-489 (1970).
8. Ackerman, C. J., and Salmon, W. D., Anal.
Biochem., 1, 327-336 (1960).
9. Singleton, W. S., et al., J. Am. Oil Chem
in liposome
preparations. Biochim. Biophys. Acta., 210(3),
486-489 (1970).
10. Ackerman, C. J., and Salmon, W. D., Anal.
Biochem., 1, 327-336 (1960).
11. Singleton, W. S., et al., J. Am. Oil
in liposome
preparations. Biochim. Biophys. Acta., 210(3),
486-489 (1970).
8. Ackerman, C. J., and Salmon, W. D., Anal.
Biochem., 1, 327-336 (1960).
9. Singleton, W. S., et al., J. Am. Oil Chem
in liposome
preparations. Biochim. Biophys. Acta., 210(3),
486-489 (1970).
10. Ackerman, C. J., and Salmon, W. D., Anal.
Biochem., 1, 327-336 (1960).
11. Singleton, W. S., et al., J. Am. Oil
in liposome
preparations. Biochim. Biophys. Acta., 210(3),
486-489 (1970).
10. Ackerman, C. J., and Salmon, W. D., Anal.
Biochem., 1, 327-336 (1960).
11. Singleton, W. S., et al., J. Am. Oil
www.chemdat.info
EMD Chemicals Inc. · USA
480 S. Democrat Road
Gibbstown, NJ 08027
Phone: 1 (800) 222-0342
Fax: 1 (800) 336-4422
www.emdchemicals.com
A subsidiary of Merck KGaA,
Darmstadt, Germany
For
a
minimum of one year when stored properly at –20 °C.
References
1. Misumi, Y., et al., Biochim. Biophys. Acta, 1131,
333-336 (1992).
2. Matter, K., and Hauri, H. P., Biochemistry, 30,
1916
can disrupt
operation.
• The pump complies with: European Economic Community (EEC) Directive 89/336/CEE,
modified 92/31/CEE and 93/68/CEE (Electromagnetic compatibility)
• Make sure all pump connections
activity of Elk1 by binding to ERK2, and prevents its interaction with MEK (IC50 = 210 nM).
Purity: ≥95% by HPLC.
1 mg € 208
ERK Inhibitor II 328007 A cell-permeable, potent, ATP-competitive inhibitor
0.0002 0.0002 210 (50%), 220 (80%),
245 (98%)1.04390.2500 2.5 L GL
1.04390.9010 10 L ST
1.04390.9030 30 L ST
1.04390.9185 185 L ST
n-Hexane 1.04391.1000 1 L GL 98.0 1 0.01 0.0002 0.0002 210 (50%), 220
synchronize cells in G1. A 50
mM (5 mg/336 µl) solution of Olomoucine (Cat. No.495624) in DMSOis also available.
1 mg
5 mg
InSolution™Olomoucine 495624 A 50 mM (5 mg/336 µl) solution of Olomoucine (Cat
277 Filamin F1888 NA NA M n/d n/d n/d
288 Anti Cy3+Cy5 C0992 NA NA M
312 Anti Cy3+Cy5 C0992 NA NA M
336 Anti Cy3+Cy5 C0992 NA NA M
360 Anti Cy3+Cy5 C0992 NA NA M
370 hnRNP-Q R5653 NA NA M y y
277 Filamin F1888 NA NA M n/d n/d n/d
288 Anti Cy3+Cy5 C0992 NA NA M
312 Anti Cy3+Cy5 C0992 NA NA M
336 Anti Cy3+Cy5 C0992 NA NA M
360 Anti Cy3+Cy5 C0992 NA NA M
370 hnRNP-Q R5653 NA NA M y y
277 Filamin F1888 NA NA M n/d n/d n/d
288 Anti Cy3+Cy5 C0992 NA NA M
312 Anti Cy3+Cy5 C0992 NA NA M
336 Anti Cy3+Cy5 C0992 NA NA M
360 Anti Cy3+Cy5 C0992 NA NA M
370 hnRNP-Q R5653 NA NA M y y
335 HDAC-8 H6412 M y n/d n/d
336 Anti Cy3+Cy5 C0992 M NA NA NA
337 HDAC-10 H3413 P y y y
338 HDAC-11 H2913 M y n/d n/d
339 HDRP/MITR H9163 P y y n/d
340 Heat Shock Factor 1 H4163 P y y
HDAC7A,Hdac7a NP_062518.2,NP_057680.3 M y y n/d
335 HDAC-8 H6412 55869 HDAC8 NP_060956.1 M y n/d n/d
336 Anti Cy3+Cy5
337 HDAC-10 H3413 362981, 83933, 170787 Hdac10,HDAC10 XP_001073452.1,NP_114408.3,NP_954668.1